CF Foundation Grants & Venture Philanthropy

The Cystic Fibrosis Foundation (CFF) is a 501(c)(3) nonprofit, founded in 1955, that funds cystic fibrosis research and care. It is also the organization most often cited as the origin case of what funders and research offices now call venture philanthropy: using an equity- or royalty-linked investment, rather than a conventional grant, to underwrite for-profit drug development in exchange for a financial return that gets reinvested in the funder’s mission. For research administrators working with foundation funders, CFF is worth understanding on two tracks: the venture-philanthropy deal that reshaped its balance sheet, and the more conventional investigator-initiated research grant programs it still runs day to day.

What “venture philanthropy” means in this context

In standard grantmaking, a foundation gives money to a researcher or institution and receives progress reports and publications in return; the funder does not have a financial stake in the outcome. Venture philanthropy, as CFF practiced it, is different: the foundation invests directly in a for-profit company’s drug-development program and negotiates a right to future royalties or milestone payments if a resulting product reaches the market. The foundation is acting more like a biotech investor than a traditional grantmaker, but the capital it deploys and any returns it realizes stay inside the nonprofit and are redirected back into its charitable mission rather than distributed to shareholders.

This distinction matters operationally as well as conceptually. A royalty- or equity-linked agreement involves intellectual-property terms, milestone definitions, and financial due diligence that look much more like a licensing negotiation (see CASRAI’s guide to royalty rate-setting methodology and royalty audit rights) than a standard notice-of-award. Research offices that only handle conventional federal or foundation grants may not have in-house expertise for this kind of instrument, which is one reason CFF’s approach is still taught as a case study — including in a Harvard Business School case on the Vertex/CFF relationship.

The CFF-Vertex story: how the model actually worked

In 2000, CFF made an initial investment of $40 million in Aurora Biosciences — a company later acquired by and merged into Vertex Pharmaceuticals — to fund a drug-discovery program aimed at correcting the malfunctioning CFTR protein that causes cystic fibrosis. Over the life of the collaboration, CFF’s cumulative investment in Vertex’s CF drug-development program reached approximately $150 million, provided alongside scientific, clinical-trial, and strategic support rather than as a passive check.

That investment helped fund development of a new drug class, CFTR modulators. The first, ivacaftor (marketed as Kalydeco), was approved by the FDA in 2012 for patients with a specific CFTR mutation — a relatively small share of the CF population at the time. In November 2014, CFF sold its royalty rights to Kalydeco and to related, not-yet-approved Vertex CF compounds to Royalty Pharma for $3.3 billion — at the time the largest royalty-monetization transaction in the pharmaceutical sector. Vertex went on to win approval for additional CFTR modulator combinations (Orkambi, Symdeko, and Trikafta), which expanded the treatable share of the CF population from roughly 5% to roughly 90%, though CFF had already sold the royalty stream on those follow-on products as part of the 2014 deal. In 2020, CFF completed the sale of its remaining royalty interest in Vertex’s CF therapies for an upfront payment of $575 million plus a potential additional $75 million tied to a future milestone. Across the two transactions, CFF has stated it secured more than $4 billion in payments from an initial outlay of roughly $150 million.

The scale of that return changed what CFF could fund. According to the foundation’s own reporting, its research and medical funding roughly doubled from about $87 million in 2012 to approximately $220 million in 2019, in the years following the first royalty sale.

How CFF deploys capital today

CFF’s venture-philanthropy activity is organized through Cystic Fibrosis Foundation Therapeutics (CFFT), the foundation’s nonprofit drug-discovery affiliate, sometimes referred to publicly as its “venture” arm. CFFT continues to structure investments in biotech and pharmaceutical partners working on CF therapies, gene-editing and gene-addition approaches, and other pipeline programs, generally negotiating some combination of milestone payments, royalties, or reinvestment rights rather than making unconditional grants to companies. Research offices at academic institutions are more likely to encounter CFFT indirectly — as a partner named in a sponsored-research or collaboration agreement with a biotech licensee — than as a direct grantor, since the venture-investment vehicle and the investigator-facing research grant programs described below are administered separately.

CFF’s investigator-initiated research grant programs

Separately from its venture-investment activity, CFF runs a standard portfolio of investigator-initiated research grants aimed at academic researchers and clinician-scientists, administered through its Research Grants program. As of CFF’s published policies, the core award types include:

Pilot and Feasibility Awards (basic research) — support for developing and testing new hypotheses or methods relevant to CF, aimed particularly at investigators establishing themselves in the field, with an eye toward generating preliminary data for a subsequent NIH or other larger-scale application. Support has been offered at up to $50,000 per year plus a capped 12% for indirect costs, for up to two years.
Clinical Pilot and Feasibility Awards — the same pilot/feasibility structure applied to projects involving human subjects, supporting new investigators and new methods in clinical CF research.
Clinical Research Awards — support for larger investigator-initiated clinical research projects (observational, interventional, translational, or epidemiologic) addressing CF diagnosis, treatment, symptom management, or pathophysiology.

Application cycles, budget caps, and eligibility details change from cycle to cycle; research administrators should always confirm current terms against CFF’s published Policies and Guidelines for the relevant award and cycle rather than relying on prior-year figures.

What this means for research administrators

A few practical points distinguish CFF (and disease-foundation funders using a similar model) from federal sponsors:

Indirect cost caps are typically well below federally negotiated rates. CFF’s published pilot-award guidance caps indirect costs at 12% of direct costs, versus federally negotiated F&A rates that are commonly 50% or higher at research universities. Grants offices should flag this early in proposal budgeting rather than after an award is made.
The foundation itself is not a purely passive funder. Because CFF’s institutional identity is built around an active, hands-on funding model (evident in the Vertex collaboration), CF-focused foundation awards may come with more foundation involvement in trial design or data-sharing expectations than a typical federal grant — confirm specific terms in the award agreement rather than assuming NIH-style hands-off administration.
Venture-investment agreements and investigator grants are legally and administratively distinct instruments at CFF, even though both ultimately serve the same charitable mission. A sponsored-research agreement tied to a CFFT-funded biotech collaboration should be routed through the same institutional review your office applies to industry-sponsored or license-linked research, not treated as a standard foundation grant.
Royalty-linked funding models are not unique to CF. Since the 2014 sale, venture philanthropy has been widely discussed as a potential model for other disease foundations, though CFF’s outcome — a single approved drug class reaching roughly 90% of the target patient population — is frequently cited as an unusually favorable result rather than a guaranteed template. Research offices evaluating a new foundation’s funding model should ask directly whether an award is a grant, a loan, or an equity/royalty-linked investment, since the three carry very different reporting, IP, and audit obligations.

Frequently asked questions

Is the Cystic Fibrosis Foundation a government agency?

No. CFF is a private 501(c)(3) nonprofit organization, not a federal or state funding body. Its research grants are foundation awards, not federal grants, and generally follow foundation-specific (not federal) reporting and indirect-cost rules.

What is the difference between CFF’s research grants and its venture philanthropy investments?

Research grants (Pilot and Feasibility, Clinical Pilot and Feasibility, Clinical Research Awards) go to academic investigators for CF-relevant research and function like conventional foundation grants. Venture philanthropy investments, made through Cystic Fibrosis Foundation Therapeutics, are capital placed into for-profit drug-development programs in exchange for royalty or milestone rights — a financial instrument, not a grant.

How much did the Cystic Fibrosis Foundation make from selling its Vertex royalties?

CFF sold its Kalydeco and related Vertex royalty rights to Royalty Pharma for $3.3 billion in November 2014, then sold its remaining royalty interest for $575 million upfront (plus up to $75 million in a potential future milestone payment) in 2020 — together more than $4 billion in returns on an original investment CFF has put at roughly $150 million.

Can other disease foundations replicate CFF’s venture philanthropy result?

Some have tried variations of the model, but CFF’s outcome depended on factors that are hard to guarantee in advance — a well-understood single-gene disease target, a committed pharmaceutical partner, and drugs that ultimately reached regulatory approval across most of the patient population. Research administrators should evaluate any venture-philanthropy-style proposal on its own IP, milestone, and risk terms rather than assuming CFF’s return is typical.

Cystic Fibrosis Foundation: Research Grants and the Venture Philanthropy Funding Model